Management Of Metastatic Breast Cancer (MBC)

Area of Science:

• Oncology
• Medical Therapeutics

Background:

• Metastatic breast carcinoma treatment is palliative, not curative.
• Current therapies include chemotherapy, hormonal, and biologic agents.
• Treatment choice depends on patient factors and disease characteristics.

Purpose of the Study:

• To evaluate the role of combination chemotherapy in metastatic breast cancer.
• To assess the benefits and risks of combination chemotherapy.
• To inform treatment decisions balancing efficacy and toxicity.

Main Methods:

• Review of current chemotherapeutic, hormonal, and biologic agents.
• Analysis of combination chemotherapy regimens.
• Consideration of patient-specific factors (age, HER-2 status, etc.).

Main Results:

• Combination chemotherapy demonstrated advantages in survival, tumor response, and time to progression.
• Adverse effects associated with combination therapy require careful management.
• Individualized treatment selection is crucial for optimizing outcomes.

Conclusions:

• Combination chemotherapy improves outcomes for metastatic breast cancer.
• Careful risk-benefit assessment is essential for effective treatment.
• Personalized therapeutic strategies are key in managing advanced breast cancer.